Ken Griffin Regenxbio Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Regenxbio Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 19,400 shares of RGNX stock, worth $194,194. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,400

Previous 18,200 6.59%

Holding current value

$194,194

Previous $212,000 4.25%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.49 - $14.39 $806,041 - $1.11 Million	76,839 Added 60.79%	203,231 $2.13 Million
Q2 2024 Aug 14, 2024	BUY	$11.51 - $21.53 $205,971 - $385,279	17,895 Added 16.49%	126,392 $1.48 Million
Q1 2024 May 15, 2024	SELL	$12.17 - $24.61 $1.26 Million - $2.55 Million	-103,547 Reduced 48.83%	108,497 $2.29 Million
Q4 2023 Feb 14, 2024	SELL	$12.89 - $20.82 $6.56 Million - $10.6 Million	-509,117 Reduced 70.6%	212,044 $3.81 Million
Q3 2023 Nov 14, 2023	BUY	$16.46 - $19.99 $1.16 Million - $1.41 Million	70,765 Added 10.88%	721,161 $11.9 Million
Q2 2023 Aug 14, 2023	SELL	$17.23 - $21.71 $1.6 Million - $2.02 Million	-92,961 Reduced 12.51%	650,396 $13 Million
Q1 2023 May 15, 2023	BUY	$18.08 - $24.55 $2.49 Million - $3.38 Million	137,520 Added 22.7%	743,357 $14.1 Million
Q4 2022 Feb 14, 2023	BUY	$20.4 - $24.73 $11.5 Million - $13.9 Million	563,266 Added 1323.12%	605,837 $13.7 Million
Q3 2022 Nov 14, 2022	BUY	$22.29 - $35.04 $948,907 - $1.49 Million	42,571 New	42,571 $1.13 Million
Q1 2022 May 16, 2022	SELL	$24.62 - $34.31 $9.58 Million - $13.3 Million	-389,044 Reduced 71.29%	156,673 $5.2 Million
Q4 2021 Feb 14, 2022	BUY	$30.19 - $40.28 $11.8 Million - $15.7 Million	389,339 Added 248.97%	545,717 $17.8 Million
Q3 2021 Nov 15, 2021	BUY	$29.09 - $45.68 $1.03 Million - $1.61 Million	35,313 Added 29.17%	156,378 $6.56 Million
Q2 2021 Aug 16, 2021	BUY	$32.46 - $40.48 $563,051 - $702,166	17,346 Added 16.72%	121,065 $4.7 Million
Q1 2021 May 17, 2021	SELL	$33.61 - $49.95 $3.68 Million - $5.47 Million	-109,459 Reduced 51.35%	103,719 $3.54 Million
Q4 2020 Feb 16, 2021	BUY	$26.52 - $49.35 $3.82 Million - $7.11 Million	144,118 Added 208.69%	213,178 $9.67 Million
Q3 2020 Nov 16, 2020	BUY	$27.01 - $40.26 $381,246 - $568,269	14,115 Added 25.69%	69,060 $1.9 Million
Q2 2020 Aug 14, 2020	BUY	$27.75 - $43.44 $287,212 - $449,604	10,350 Added 23.21%	54,945 $2.02 Million
Q1 2020 May 15, 2020	SELL	$21.5 - $54.2 $104,834 - $264,279	-4,876 Reduced 9.86%	44,595 $1.44 Million
Q4 2019 Feb 14, 2020	SELL	$34.54 - $44.87 $3.69 Million - $4.79 Million	-106,788 Reduced 68.34%	49,471 $2.03 Million
Q3 2019 Nov 14, 2019	BUY	$31.84 - $50.88 $3.9 Million - $6.23 Million	122,409 Added 361.62%	156,259 $5.56 Million
Q2 2019 Aug 14, 2019	SELL	$42.0 - $59.29 $16.1 Million - $22.8 Million	-384,273 Reduced 91.9%	33,850 $1.74 Million
Q1 2019 May 15, 2019	SELL	$40.82 - $62.45 $879,099 - $1.34 Million	-21,536 Reduced 4.9%	418,123 $0
Q4 2018 Feb 14, 2019	SELL	$39.11 - $75.15 $2.04 Million - $3.92 Million	-52,141 Reduced 10.6%	439,659 $18.4 Million
Q3 2018 Nov 13, 2018	BUY	$65.0 - $82.15 $29.6 Million - $37.5 Million	456,151 Added 1279.56%	491,800 $0
Q2 2018 Aug 10, 2018	SELL	$27.2 - $74.35 $20.3 Million - $55.5 Million	-746,007 Reduced 95.44%	35,649 $0
Q1 2018 May 11, 2018	SELL	$24.05 - $37.5 $4.96 Million - $7.73 Million	-206,096 Reduced 20.87%	781,656 $23.3 Million
Q4 2017 Feb 09, 2018	BUY	$26.0 - $34.6 $9.84 Million - $13.1 Million	378,612 Added 62.16%	987,752 $32.8 Million
Q3 2017 Nov 09, 2017	BUY	$18.0 - $32.95 $11 Million - $20.1 Million	609,140	609,140 $20.1 Million

Others Institutions Holding RGNX

# of Institutions

197

Shares Held

43.2M

Call Options Held

104K

Put Options Held

478K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $433M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account